close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Nexalin Technology, Inc.

< Previous 1 2 Next >
News headline image
Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on April 3
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Nexalin Technology Announces Initiation of Patient Recruitment for UCSD’s TBI & PTSD Clinical Study Following IRB Approval
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity in Clinical Trials for mTBI and PTSD Treatment
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Nexalin’s Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session, Today, January 23
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Nexalin Technology CEO Mark White Issues Letter to Shareholders Highlighting Recent Achievements and Outlook for 2025
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
New Peer-Reviewed Publication Validates Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Nexalin Technology CEO Provides Letter to Shareholders
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on November 5th
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Nexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
New Study Shows Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer’s Patients
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Nexalin Technology Participates in Congressional Roundtable Focused on Emerging Virtual Therapeutic Options for Opioid Treatment
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Nexalin Technology Selected to Join Industry Coalition: Breaking Barriers to Substance Use Recovery
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Nexalin Technology Announces Closing of $5.2 Million Public Offering
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Nexalin Technology Announces Pricing of $5.2 Million Public Offering
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
FDA Provides Feedback and Reaches Consensus on Nexalin’s Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today